Francesco Menzella Selected Research

mepolizumab

4/2022	Effects of anti-IL5 biological treatments on blood IgE levels in severe asthmatic patients: A real-life multicentre study (BIONIGE).
2/2021	Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life.
1/2021	Successful treatment with benralizumab in a patient with eosinophilic granulomatosis with polyangiitis refractory to mepolizumab.
1/2021	A Real-World Evaluation of Clinical Outcomes of Biologicals and Bronchial Thermoplasty for Severe Refractory Asthma (BIOTERM).
1/2020	Biologics and Bronchial Thermoplasty for severe refractory asthma treatment: From eligibility criteria to real practice. A cross-sectional study.
1/2020	The importance of being not significant: Blood eosinophils and clinical responses do not correlate in severe asthma patients treated with mepolizumab in real life.
1/2019	Efficacy and steroid-sparing effect of benralizumab: has it an advantage over its competitors?
1/2019	Analysis of the drop-out rate in patients receiving mepolizumab for severe asthma in real life.
1/2017	Near-fatal asthma responsive to mepolizumab after failure of omalizumab and bronchial thermoplasty.
12/2016	The clinical profile of benralizumab in the management of severe eosinophilic asthma.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Francesco Menzella Research Topics

Disease

51	Asthma (Bronchial Asthma) 05/2022 - 05/2011
5	Inflammation (Inflammations) 04/2022 - 01/2016
5	COVID-19 07/2021 - 01/2020
4	Pneumonia (Pneumonitis) 04/2021 - 11/2010
3	Fever (Fevers) 01/2022 - 01/2019
2	Rhinosinusitis 01/2022 - 01/2021
2	Sinusitis 01/2022 - 01/2021
2	Headache (Headaches) 01/2022 - 01/2021
2	Nasal Polyps (Nasal Polyp) 01/2022 - 01/2021
2	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 07/2021 - 11/2010
2	Respiratory Insufficiency (Respiratory Failure) 07/2021 - 01/2018
2	Virus Diseases (Viral Diseases) 03/2021 - 01/2020
2	Infections 10/2020 - 01/2020
2	Bronchiectasis 01/2020 - 05/2019
2	Eosinophilia 01/2015 - 01/2015
1	Human Influenza (Influenza) 01/2022
1	Pneumococcal Infections 04/2021
1	Systemic Vasculitis 01/2021
1	Vasculitis (Vasculitides) 01/2021
1	Churg-Strauss Syndrome (Allergic Angiitis) 01/2021
1	Chronic Urticaria 01/2021
1	Malignant Mesothelioma 01/2021
1	Nasopharyngitis 01/2021
1	Neoplasms (Cancer) 01/2021
1	Bronchitis 01/2021
1	Respiratory Tract Infections (Respiratory Tract Infection) 10/2020
1	Cytokine Release Syndrome 01/2020
1	Fibrosis (Cirrhosis) 01/2020
1	Gastroesophageal Reflux (GERD) 01/2020
1	Lung Injury 01/2020
1	Food Hypersensitivity (Food Allergy) 05/2019
1	Allergic Rhinitis 05/2019
1	Pulmonary Eosinophilia (Eosinophilic Pneumonia) 01/2019
1	Necrosis 01/2018
1	Glycogen Storage Disease Type II (Pompe's Disease) 01/2018
1	Glycogen Storage Disease (Glycogenosis) 01/2018
1	Bronchial Spasm 01/2017
1	Pulmonary Atelectasis 01/2015

Drug/Important Bio-Agent (IBA)

18	Adrenal Cortex Hormones (Corticosteroids)IBA 05/2022 - 01/2015
15	benralizumabIBA 04/2022 - 01/2015
14	mepolizumabIBA 04/2022 - 01/2015
14	Biological ProductsIBA 04/2022 - 01/2016
14	Omalizumab (Xolair)FDA Link 01/2022 - 05/2011
6	Immunoglobulin E (IgE)IBA 04/2022 - 05/2011
6	Monoclonal AntibodiesIBA 03/2021 - 01/2015
6	Interleukin-5 (Interleukin 5)IBA 10/2020 - 01/2015
4	Biomarkers (Surrogate Marker)IBA 01/2021 - 01/2015
4	Pharmaceutical PreparationsIBA 01/2021 - 01/2019
4	CytokinesIBA 10/2020 - 01/2015
3	Oxygen (Dioxygen)IBA 01/2020 - 12/2012
3	SteroidsIBA 10/2019 - 05/2011
3	reslizumabIBA 01/2019 - 01/2015
2	Adrenergic Receptors (Adrenergic Receptor)IBA 01/2021 - 01/2021
2	tocilizumab (atlizumab)FDA Link 11/2020 - 01/2020
2	Interleukin-13IBA 10/2020 - 01/2015
1	Messenger RNA (mRNA)IBA 05/2022
1	Ubiquitin Thiolesterase (Ubiquitin Carboxy-Terminal Hydrolase)IBA 05/2022
1	Conjugate VaccinesIBA 04/2021
1	anti-IgE antibodiesIBA 03/2021
1	Antiviral Agents (Antivirals)IBA 03/2021
1	Muscarinic AntagonistsIBA 01/2021
1	Theophylline (Theon)FDA LinkGeneric 01/2021
1	Leukotriene Antagonists (Leukotriene Receptor Antagonists)IBA 01/2021
1	AsbestosIBA 01/2021
1	Acute-Phase Proteins (Acute-Phase Protein)IBA 11/2020
1	Interleukin-6 (Interleukin 6)IBA 11/2020
1	Thymic Stromal LymphopoietinIBA 10/2020
1	Bacterial LysatesIBA 10/2020
1	Chemokine CCL24IBA 10/2020
1	Interleukin-4 (Interleukin 4)IBA 10/2020
1	ChemokinesIBA 10/2020
1	Interleukin-33IBA 10/2020
1	beta-Lactamases (beta-Lactamase)IBA 01/2020
1	mesoglycanIBA 01/2019
1	dupilumabIBA 01/2019
1	InterleukinsIBA 01/2019
1	Anti-Bacterial Agents (Antibiotics)IBA 12/2018
1	alpha-Glucosidases (Acid Maltase)IBA 01/2018
1	AcidsIBA 01/2018
1	EnzymesIBA 01/2018
1	GlycogenIBA 01/2018
1	MicroRNAs (MicroRNA)IBA 01/2018
1	GlucosidasesIBA 01/2018
1	FibrinIBA 01/2015
1	Interleukin-2 (IL2)IBA 01/2015
1	lebrikizumabIBA 01/2015
1	Bronchodilator Agents (Bronchodilators)IBA 01/2015
1	Daclizumab (Zenapax)FDA Link 01/2015

Therapy/Procedure

16	Therapeutics 02/2021 - 05/2011
9	Bronchial Thermoplasty 05/2022 - 07/2014
5	Biological Therapy 01/2022 - 01/2017
3	Noninvasive Ventilation 07/2021 - 01/2015
3	Artificial Respiration (Mechanical Ventilation) 01/2020 - 01/2018
3	Precision Medicine 01/2020 - 01/2018
1	Hospital to Home Transition 01/2022
1	Continuous Positive Airway Pressure 07/2021
1	Nebulizers and Vaporizers (Inhaler) 01/2021
1	Self Administration (Administration, Self) 01/2021
1	Immunomodulation 10/2020
1	Tracheostomy 01/2018